Lupin’s arm launches Generic Aricept tablets in the US

31 Mar 2016 Evaluate

Lupin’s US subsidiary -- Lupin Pharmaceuticals has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept Tablets, 23mg. Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type. Aricept had US sales of $47.1 million (IMS MAT December 2015).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin Share Price

2163.00 -15.20 (-0.70%)
20-Jan-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.70
Dr. Reddys Lab 1184.30
Cipla 1378.30
Zydus Lifesciences 875.05
Lupin 2163.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×